Screener
Kymera Therapeutics KYMR Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $8,918 | $4,015 |
| Accrued expenses (Note 8) | 48,476 | 42,274 |
| Deferred revenue | — | 22,925 |
| Operating lease liabilities | 12,119 | 11,941 |
| Finance lease liabilities | 1,577 | 1,815 |
| Other current liabilities | 236 | 242 |
| Total current liabilities | $71,326 | $83,212 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's deferred revenue?
- Kymera Therapeutics (KYMR) reported deferred revenue of $0 in Q2 2026.
- How has Kymera Therapeutics's deferred revenue changed year-over-year?
- Kymera Therapeutics's deferred revenue decreased by 100.0% year-over-year, from $40M to $0.
- What is the long-term trend for Kymera Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Kymera Therapeutics's deferred revenue has grown at a -24.4% compound annual growth rate (CAGR), from $92.55M to $22.93M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Kymera Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude